This AI diagnostics stock is a holding in Wood's ARKK and ARKG ETFs.
The fund company focuses on the right industries, but these industries' stocks require a very particular economic backdrop and market environment.
This Ark Invest biotech stock pick, with 55% potential upside, garnered a vote of confidence from Jefferies last week.
There was double trouble for this beaten-down biotech stock.
These companies could generate explosive growth over time.
The tide has gone out on ARK Invest's ETFs, and it doesn't look pretty.
Teladoc's share performance has reflected its earnings struggles...
You don't need to buy her picks, but it's worth understanding them.
Growth-orientated funds could face ongoing pressure in a high-interest-rate environment.
What's good for Wood and Ark Invest might not be good for other investors.